Lyra Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Carmichael S. Roberts Jr.
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 480 Arsenal Way Watertown MA United States of America 02472
- IPO Date
- May 1, 2020
- CIK
- 0001327273
- Website
- lyratherapeutics.com
- Similar Companies
- Business
- Lyra Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development and commercialization of drug and delivery solutions for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. The company’s core products include LYR-210 and LYR-220, which are bioabsorbable nasal implants designed to be administered via a brief, in-office procedure to deliver continuous anti-inflammatory mometasone furoate therapy locally to sinonasal tissues for up to six months. These products leverage Lyra’s proprietary XTreo™ platform, which enables precision delivery of medication directly to affected ear, nose, and throat (ENT) tissues, addressing the significant unmet medical need of persistent CRS symptoms in patients. Lyra primarily operates in the biotechnology and pharmaceutical sector, targeting patients with CRS in the United States and aiming for international expansion through partnerships. Recent major developments include positive Phase 3 ENLIGHTEN 2 clinical trial results for LYR-210 presented in 2025, showing statistically significant symptom improvements compared to control, with ongoing preparations for a confirmatory Phase 3 trial following FDA feedback to support a new drug application (NDA) submission. In 2025, Lyra resumed manufacturing activities, engaged with the FDA for regulatory alignment, and implemented a 1-for-50 reverse stock split to maintain Nasdaq listing compliance. Additionally, Lyra maintains a strategic partnership and exclusive license agreement with LianBio for the development and commercialization of LYR-210 in Greater China, South Korea, Singapore, and Thailand, providing Lyra with upfront payments and milestone-based revenues. The company continues to advance its pipeline with clinical studies on LYR-220, broadening its treatment addressable market within CRS. Founded in 2014 and headquartered in Boston, Massachusetts, Lyra Therapeutics operates primarily within the United States, with growing international collaborations. The company focuses on innovative treatments for ENT diseases, primarily CRS, and aims to provide long-acting, localized treatments that break the cycle of conventional medical management. Lyra Therapeutics remains a single operating segment entity driven by proprietary drug delivery technology and an expanding clinical portfolio targeting CRS patients both with and without nasal polyps.
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
Gold Rises Sharply; Lyra Therapeutics Shares Plunge
Lyra Therapeutics Provides Corporate Update
Lyra Therapeutics (NASDAQ:LYRA) Trading Up 0.3% – Time to Buy?
Lyra Therapeutics (NASDAQ:LYRA) Trading Up 4.5% – Should You Buy?
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
This penny stock just spiked 550% in a day; Time to buy?
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update